Bactericidal activity and postantibiotic effect of levofloxacin against anaerobes

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 10, 1999, Pages 2547-2549

  Pendland, Susan L ^a   Diaz Linares, Mariela ^a   Garey, Kevin W ^a   Woodward, Jennifer G ^b   Ryu, Seonyoung ^c   Danziger, Larry H ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b ADVOCATE LUTHERAN GENERAL HOSPITAL   (United States)

^c Cedars Sinai Health System   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; LEVOFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANAEROBIC BACTERIUM; ARTICLE; BACTERICIDAL ACTIVITY; BACTEROIDES FRAGILIS; BACTEROIDES THETAIOTAOMICRON; CLOSTRIDIUM PERFRINGENS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PEPTOSTREPTOCOCCUS; PRIORITY JOURNAL; STRAIN DIFFERENCE;

EID: 0032823098     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.10.2547     Document Type: Article

References (18)

1. Bauernfeind, A. 1997. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J. Antimicrob. Chemother. 40:639-651.
2. Chalkley, L. J., and H. J. Koornhof. 1985. Antimicrobial activity of ciprofloxacin against Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus determined by the killing curve method: antibiotic comparisons and synergistic interactions. Antimicrob. Agents Chemother. 28:331-342.
3. Chien, S.-C., M. C. Rogge, L. G. Gisclon, C. Curtin, F. Wong, J. Natarajan, R. R. Williams, C. L. Fowler, W. K. Cheung, and A. T. Chow. 1997. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses. Antimicrob. Agents Chemother. 41:2255-2260.
4. Chien, S.-C., F. A. Wong, C. L. Fowler, S. V. Callery-D'Amico, R. R. Williams, R. Nayak, and A. T. Chow. 1998. Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers. Antimicrob. Agents Chemother. 42:885-888.
5. Craig, W. A., and S. Gudmundsson. 1996. Postantibiotic effect p. 296-329. In V. Lorian (ed.), Antibiotics in laboratory medicine, 4th ed. The Williams & Wilkins Co., Baltimore, Md.
6. Fu, K. P., B. Foleno, and M. E. Rosenthale. 1992. The postantibiotic suppressive effect of L-ofloxacin, an optically active isomer of ofloxacin. Diagn. Microbiol. Infect. Dis. 15:375-378.
7. Goldstein, E. J. C. 1996. Possible role for the fluoroquinolones (levofloxacin, grepafloxacin, trovafloxacin, clinafloxacin, sparfloxacin, and DU-6859a) in the treatment of anaerobic infections: review of current information on efficacy and safety. Clin. Infect. Dis. 23(Suppl. 1):S25-S30.
8. Hecht, D. W., and H. M. Wexler. 1996. In vitro susceptibility of anaerobes to quinolones in the United States. Clin. Infect. Dis. 23(Suppl. 1):S2-S8.
9. Houston, A. K., and R. N. Jones. 1994. Postantibiotic effect of DU-6859a and levofloxacin as compared to ofloxacin. Diagn. Microbiol. Infect. Dis. 18:57-59.
10. Lewin, C. S., I. Morrissey, and J. T. Smith. 1991. The mode of action of quinolones: the paradox in activity of low and high concentrations and activity in anaerobic environment. Eur. J. Clin. Microbiol. Infect. Dis. 10: 240-248.
11. Licata, L., C. E. Smith, R. M. Goldschmidt, J. F. Barrett, and M. Frosco. 1997. Comparison of the postantibiotic and postantibiotic sub-MIC effects of levofloxacin and ciprofloxacin on Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob. Agents Chemother. 41:950-955.
12. National Committee for Clinical Laboratory Standards. 1993. Methods for antimicrobial susceptibility testing of anaerobic bacteria, 3rd. ed. Approved standard. NCCLS document M11-A3, vol. 13, no. 26. National Committee for Clinical Laboratory Standards, Villanova, Pa.
13. National Committee for Clinical Laboratory Standards. 1992. Methods for determining bactericidal activity of antimicrobial agents; tentative guideline. NCCLS document M26-T, vol. 12, no. 19. National Committee for Clinical Laboratory Standards, Villanova, Pa.
14. 13a. Pendland, S. L., M. Diaz-Linares, J. G. Woodward, S. Ryu, and L. H. Danziger. 1996. Bactericidal activity of levofloxacin (L) against Bacteriodes (B), abstr. E9, p. 82. In Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
15. Spangler, S. K., M. R. Jacobs, and P. C. Appelbaum. 1997. Bactericidal activity of DU-6859a compared to activities of three quinolones, three β-lactams, clindamycin, and metronidazole against anaerobes as determined by time-kill methodology. Antimicrob. Agents Chemother. 41:847-849.
16. Spangler, S. K., G. Lin, M. R. Jacobs, and P. C. Appelbaum. 1998. Postantibiotic effect and postantibiotic sub-MIC effect of levofloxacin compared to those of ofloxacin, ciprofloxacin, erythromycin, azithromycin, and clarithromycin against 20 pneumococci. Antimicrob. Agents Chemother. 42:1253-1255.
17. Tanaka, M., K. Hoshino, M. Hohmura, et al. 1996. Effect of growth conditions on antimicrobial activity of DU-6859a and its bactericidal activity determined by the killing curve method. J. Antimicrob. Chemother. 37:1091-1102.
18. Zahinski, R. A., K. J. Walker, A. J. Larsson, J. A. Moody, G. W. Kaatz, and J. C. Rotschafer. 1995. Effect of aerobic and anaerobic environments on antistaphylococcal activities of five fluoroquinolones. Antimicrob. Agents Chemother. 39:507-512.